Proliferating cell nuclear antigen (PCNA) and p53 protein expression in ameloblastoma and adenomatoid adontogenic tumor

Brazilian Dental Journal

Carlos Augusto Galvão Barboza²  Leão Pereira Pinto¹  Roseana De Almeida Freitas¹  Antônio De Lisboa Lopes Costa¹  Lélia Batista De Souza¹ 

[1] ,Federal University of Rio Grande do Norte Faculty of Dentistry Department of MorphologyNatal RN ,Brazil

关键词: ameloblastoma;    adenomatoid odontogenic tumor;    PCNA;    p53 protein;   

DOI  :  10.1590/S0103-64402005000100010

来源: SciELO

【 摘 要 】

In this study, proliferating cell nuclear antigen (PCNA) and p53 protein expressions were analyzed in 16 cases of ameloblastoma and 8 cases of adenomatoid odontogenic tumor (AOT). The cases of ameloblastoma consisted of solid type tumors and histologic arrangements of different subtypes were observed. In some specimens, more than one histologic subtype was identified in the same lesion, and each tumor was categorized according to the predominant cell pattern. The odontogenic tumors were grouped as follows: follicular ameloblastoma (n=7), plexiform ameloblastoma (n=4), acanthomatous + follicular ameloblastoma (n=3), basal cell ameloblastoma (n=2), adenomatoid odontogenic tumor (n=8). PCNA immunohistochemical expression revealed stronger quantitative labeling index for the follicular ameloblastoma, while for p53 protein the strongest quantitative labeling index was detected in the plexiform type. Nevertheless, statistical analysis using ANOVA and Tukey's test did not detect significant differences (p>0.05) among the histologic subtypes of ameloblastoma. The findings of this study suggest that the different histologic patterns of ameloblastoma did not show a direct correlation with their clinical behavior and consequently with the prognosis of the cases. The results also indicated that the ameloblastoma has greater proliferative potential than the AOT, which can contribute to explain its more aggressive and invasive characteristics.

【 授权许可】

CC BY   
 All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License